Literature DB >> 3402460

Glycosylation of three molecular forms of human alpha 1-acid glycoprotein having different interactions with concanavalin A. Variations in the occurrence of di-, tri-, and tetraantennary glycans and the degree of sialylation.

M F Bierhuizen1, M De Wit, C A Govers, W Ferwerda, C Koeleman, O Pos, W Van Dijk.   

Abstract

Human alpha 1-acid glycoprotein (AGP) was separated into a non-bound (AGP-A; 46%), a retarded (AGP-B; 39%) and a bound fraction (AGP-C; 15%) using concanavalin A (ConA)-Sepharose chromatography. The apparent molecular masses, as determined by SDS-PAGE, of the three fractions were 43.5, 42.3 and 41.2 kDa, respectively. The occurrence of N-linked di-, tri- and tetraantennary glycans on these three molecular forms (AGP-A, -B, and -C) was studied by sequential lectin-affinity chromatography of the 14C-labelled glycopeptides. These were obtained by extensive pronase treatment followed by N-[14C]acetylation of the peptide moieties. The glycopeptides of AGP-A did not bind to ConA-Sepharose whereas for AGP-B and AGP-C 18% and 44%, respectively, of the glycopeptides were bound as diantennary structures. Glycopeptide fractions of all three forms of AGP which were not bound to ConA-Sepharose were shown to contain equal amounts of both tri- and tetraantennary glycans by chromatography with Phaseolus vulgaris leukoagglutinating lectin (L-PHA). With the assumption that each molecule contains five glycosylation sites, it could be shown that AGP-A contains no diantennary structures whereas AGP-B and AGP-C contain one and two diantennary structures, respectively. In addition each of the molecular forms contains equal amounts of tri- and tetraantennary structures on the remaining glycosylation sites. The results of this study, therefore, exclude a uniformity of glycan chains in the three molecular forms of AGP. The degree of sialylation of each of the molecular forms was investigated by chromatography on L-PHA-agarose and Ricinus communis agglutinin-I--agarose both before and after desialylation of the glycopeptides. It was shown that about 90% of the biantennary glycans of both AGP-B and AGP-C were disialylated while the remainder were monosialylated. The degree of sialylation of the tri- and tetraantennary glycans was identical for the three molecular forms. In each case, one or more terminal galactose residues occurred on at least 20% of the tri- and 65% of the tetraantennary chains. It is suggested that the decrease in the exposure of galactose residues from AGP-A to AGP-C is related to the concomittant decrease in branching of the glycans of the three molecular forms. The relevance of these findings to studies on the function of AGP during inflammatory and liver diseases is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402460     DOI: 10.1111/j.1432-1033.1988.tb14208.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  30 in total

1.  Increased alpha3-fucosylation of alpha1-acid glycoprotein in Type I diabetic patients is related to vascular function.

Authors:  D C Poland; C G Schalkwijk; C D Stehouwer; C A Koeleman; B van het Hof; W van Dijk
Journal:  Glycoconj J       Date:  2001-03       Impact factor: 2.916

2.  Role of biantennary glycans and genetic variants of human alpha1-acid glycoprotein in enantioselective binding of basic drugs as studied by high performance frontal analysis/capillary electrophoresis.

Authors:  Y Kuroda; Y Kita; A Shibukawa; T Nakagawa
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

3.  Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein.

Authors:  M J Treuheit; C E Costello; H B Halsall
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

4.  Inflammation-induced changes in expression and glycosylation of genetic variants of alpha 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice.

Authors:  W van Dijk; O Pos; M E van der Stelt; H J Moshage; S H Yap; L Dente; P Baumann; C B Eap
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

5.  Changes in the serum concentration and the glycosylation of human alpha 1-acid glycoprotein and alpha 1-protease inhibitor in severely burned persons: relation to interleukin-6 levels.

Authors:  O Pos; M E van der Stelt; G J Wolbink; M W Nijsten; G L van der Tempel; W van Dijk
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

6.  Studies on the interaction between hyaluronan and a rat colon cancer cell line.

Authors:  C Samuelsson; S Gustafson
Journal:  Glycoconj J       Date:  1998-02       Impact factor: 2.916

7.  Endocytosis of alpha 1-acid glycoprotein variants and of neoglycoproteins containing mannose derivatives by a mouse hybridoma cell line (2C11-12). Comparison with mouse peritoneal macrophages.

Authors:  V Pimpaneau; P Midoux; G Durand; P De Baetselier; M Monsigny; A C Roche
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

8.  Biliary alpha 1-acid glycoprotein concentrations in gallstone-free controls and in patients with multiple or solitary cholesterol gallstones.

Authors:  H Nuutinen; M Abei; J Schwarzendrube; S Ginanni Corradini; R M Walsh; P Kawczak; R T Holzbach
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

9.  Prevalence of tri- and tetraantennary glycans of human alpha 1-acid glycoprotein in release of macrophage inhibitor of interleukin-1 activity.

Authors:  P N Bories; J Feger; N Benbernou; J D Rouzeau; J Agneray; G Durand
Journal:  Inflammation       Date:  1990-06       Impact factor: 4.092

10.  Severe rheumatoid arthritis prohibits the pregnancy-induced decrease in alpha3-fucosylation of alpha1-acid glycoprotein.

Authors:  E C Havenaar; J S Axford; E C Brinkman-van der Linden; A Alavi; E C Van Ommen; B van het Hof; T Spector; A Mackiewicz; W Van Dijk
Journal:  Glycoconj J       Date:  1998-07       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.